Vascular Solutions to Present at the 33rd Annual Canaccord Genuity Growth
MINNEAPOLIS, July 31, 2013 (GLOBE NEWSWIRE) -- Vascular Solutions, Inc.
(Nasdaq:VASC) today announced that the Company is scheduled to present at the
33^rd Annual Canaccord Genuity Growth Conference in Boston on Wednesday,
August 14^th at 8:30am (EDT).
James Hennen, Chief Financial Officer of Vascular Solutions, will deliver the
Company's presentation.To hear the live audio webcast and view the slides of
the Vascular Solutions' presentation, go to the investor relations page of the
Company's web site www.vasc.com and click on the "Investor Conferences" icon a
few minutes prior to start time to download any necessary software.
About Canaccord Genuity
Canaccord Genuity is a leading independent financial services firm committed
to fostering the entrepreneurial economy by bringing corporate and
institutional clients a unique perspective on global investment opportunities.
More information is available at www.canaccordgenuity.com
About Vascular Solutions
Vascular Solutions, Inc. is an innovative medical device company that focuses
on developing unique clinical solutions for coronary and peripheral vascular
procedures.The company's product line consists of over 75 products in three
categories: catheter products, hemostat products and vein products.Vascular
Solutions delivers its products to interventional cardiologists,
interventional radiologists, electrophysiologists, and vein specialists
through its direct U.S. sales force and international independent distributor
The information in this press release contains forward-looking statements,
including statements regarding the international availability of the Venture
catheter and expectations about the product's sales, that involve risks and
uncertainties. Our actual results could differ materially from those
anticipated in these forward-looking statements. Important factors that may
cause such differences include those discussed in our Annual Report on Form
10-K for the year ended December 31, 2012 and other recent filings with the
Securities and Exchange Commission. The risks and uncertainties include,
without limitation, risks associated with the need for adoption of our new
products, lack of sustained profitability, exposure to intellectual property
claims, significant variability in quarterly results, exposure to possible
product liability claims, the development of new products by others, doing
business in international markets, the availability of third party
reimbursement, and actions by the FDA.
For further information, connect to www.vasc.com.
CONTACT: James Hennen, CFO
Phil Nalbone, VP
Vascular Solutions, Inc.
Press spacebar to pause and continue. Press esc to stop.